Flatiron Health at ASH 2024
Booth #2142
Flatiron is excited to attend and present our research at the 2024 ASH Annual Meeting, showcasing how our evidence solutions can be leveraged to accelerate hematologic cancer research across the therapeutic development lifecycle.
Tailored hematology evidence solutions for every phase of the biopharma lifecycle
At Flatiron, we’re constantly pushing the realm of possibilities with evidence solutions that support oncology portfolios across the development lifecycle.
At ASH, we’re excited to showcase innovative hematology solutions to advance evidence generation, including:
-
Real-world data (RWD) across 4 of the largest oncology markets in the world and multimodal data
-
Real-world evidence (RWE) services leveraging Flatiron’s in-house expertise
-
Our clinical trials technology and services enabling prospective evidence generation
Our accepted research demonstrates RWD’s potential to create evidence that can identify treatment gaps in current therapies and improve understanding of treatment options for patients across a variety of hematologic cancers.
Featured session
A New Era in Research: Pragmatic Prospective Real-World Studies
When: Saturday December 7 at 3:45 PM PT
Where: Room 5A – Upper Level – San Diego Convention Center
Clinical trials have long faced challenges like inefficient data collection, extended timelines, and a lack of diversity in patient populations. The need for more efficient and inclusive trials is urgent as Sponsors aim to accelerate timelines while managing site capacity and ensuring patient safety. In this presentation, Dr. Majd Ghanim will discuss how prospective real-world studies are using technology and data to address these persistent issues. A blinded case study will demonstrate how Flatiron’s approach is already accelerating timelines, improving diversity, and driving more efficient, inclusive trials.
presenter
Majd Ghanim, MD, MSCR
Medical Director, Flatiron Health
Featured solutions
Real-World Data
Our flexible real-world data configurations are tailored to address the specific needs of your oncology portfolio and now encompass more than 550K hematologic oncology patient journeys, 4 of the largest oncology markets in the world, 6+ hematologic tumor types, and multimodal data.
Real-World Evidence Services
We know real-world data. We deliver oncology real-world evidence. Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your hematologic oncology portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.
Protocol Optimization and Patient Identification by Flatiron
An adaptive set of data and tech-enabled services designed to optimize clinical trial protocols, appropriately match the right trials to the right sites, and identify trial-eligible patients at the point of care.
Prospective Evidence Generation
We help sponsors generate prospective evidence through the pragmatic design and execution of low-interventional or observational studies enabled by our proprietary technology and centralized services.
Flatiron experts at ASH
Stop by booth #2142 to meet one of our scientific and medical experts, learn more about our vast, contemporaneous real-world data, and discover what it looks like to work with our engaged research community.
Our research
Read more about our accepted research at this year’s conference.
The Impact of Structural Racism and Social Determinants of Health on Fluorescence in Situ Hybridization Testing Among Patients with Multiple Myeloma
Author affiliations: Flatiron Health
Using the nationwide Flatiron Health EHR-derived, de-identified database, this study examined the impact of structural racism and social determinants of health (SDOH) on fluorescence in situ hybridization testing in patients with multiple myeloma.
See this research
Date: Sunday, December 8
Time: 6:00 - 8:00 PM
Poster Session: 906
Poster Code: 3719
Connect with a flatiron expert
Amy Pierre
Senior Clinical Director
Connect on LinkedIn
Real-World Characteristics and Survival Outcomes of Patients With Mantle Cell Lymphoma Treated With Covalent Bruton's Tyrosine Kinase Inhibitors in First-Line
Author affiliations: Flatiron Health
The advancement of covalent Bruton's tyrosine kinase inhibitors (cBTKi) into the first-line setting may be an attractive treatment approach for patients with Mantle Cell Lymphoma (MCL), however, current prospective studies have not demonstrated a survival advantage.
See this research
Date: Saturday, December 7
Time: 5:30 - 7:30 PM
Poster Session: 623
Poster Code: 1655
Connect with a flatiron expert
James Roose
Senior Research Scientist
Connect on LinkedIn
Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma
Author affiliations: Flatiron Health, Johnson & Johnson, University of North Carolina, Harvard Medical School, Dana Farber Cancer Institute, Mayo Clinic, Massachusetts General Hospital, University of Alabama at Birmingham, Feinberg School of Medicine
This research showcases the potential of a novel real-world progression algorithmic approach to determining progression-free survival (PFS) in patients with Multiple Myeloma (MM), presenting a comprehensive assessment of important design choices for a real-world progression algorithm and the potential of using RWD to assess PFS in MM.
See this research
Date: Sunday, December 8
Time: 6:00 - 8:00 PM
Poster Session: 907
Poster Code: 3762
Connect with a flatiron expert
James Roose
Senior Research Scientist
Connect on LinkedIn
Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort
Author affiliations: Flatiron Health, Kite Pharma, University of Kansas Cancer Center, Central Care Cancer Center, Fred Hutchinson Cancer Research Center, Mosaic Life Care, Memorial Sloan Kettering Cancer Center
This study examined over 10K LBCL patients from the US nationwide Flatiron Health EHR-derived database to understand treatment patterns and factors linked to death before starting second-line therapy. The researchers highlighted key factors that predict death before 2L, including factors associated with a patient's International Prognostic Index (IPI), and their socio-economic status.
See this research
Date: Saturday, December 7
Time: 5:30 - 7:30 PM
Poster Session: 906
Poster Code: 2367
Connect with a flatiron expert
Jeremy Snider
Senior Research Scientist
Connect on LinkedIn
Evaluating Reasons for Differences in Real-World (RW) Clinical Outcomes among Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) on Covalent BTK Inhibitors (cBTKis)
Author affiliations: Flatiron Health, City of Hope, BeiGene, Fred Hutchinson Cancer Research Center, Mayo Clinic
Building off prior research on real-world time to next treatment and overall survival among relapsed/refractory patients with Mantle Cell Lymphoma who were treated with covalent Bruton's tyrosine kinase inhibitors, this study aimed to further assess treatment patterns, reasons for cBTKi discontinuation and compare effectiveness for patients R/R MCL patients treated with different cBTKi monotherapies.
See this research
Date: Sunday, December 8
Time: 6:00 - 8:00 PM
Poster Session: 906
Poster Code: 3732
Connect with a flatiron expert
Amy Pierre
Senior Clinical Director
Connect on LinkedIn
Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) therapy targeting FLT3, IDH1, or IDH2
Author affiliations: Flatiron Health, O’Neal Comprehensive Cancer Center at University of Alabama Birmingham, University of Colorado School of Medicine
Acute Myeloid Leukemia (AML) is the most common and fatal acute leukemia in adults. This study examined 482 adults with AML treated with FLT3- or IDH-targeted TKIs from the nationwide Flatiron Health EHR-derived database, revealing overall poor survival outcomes regardless of treatment timing.
See this research
Date: Sunday, December 8
Time: 6:00 - 8:00 PM
Poster Session: 908
Poster Code: 3808
Connect with a flatiron expert
Eric Meadows
Director, Scientific Engagement
Connect on LinkedIn
A Real-World (RW) Analysis of the Relationship between Epstein-Barr Virus (EBV) Positivity and Baseline Characteristics, Treatment Patterns and Clinical Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)
Author affiliations: Flatiron Health, UT Southwestern Medical Center
By analyzing data from over 5,900 patients from the Flatiron Health EHR-derived database, the research revealed that while patients received similar treatments, those with EBV+ DLBCL had significantly worse survival rates than those with DLBCL not otherwise specified, emphasizing the need for better treatment strategies to improve outcomes for this specific patient group.
See this research
Date: Sunday, December 8
Time: 6:00 - 8:00 PM
Poster Session: 906
Poster Code: 3719
Connect with a flatiron expert
Eric Meadows
Director, Scientific Engagement
Connect on LinkedIn
Want to learn more about how Flatiron’s Evidence Solutions can support research across your hematologic cancer portfolio?
Leverage Flatiron’s industry-leading oncology solutions to unlock global insights in hematologic cancer research, including:
-
Real-world data (RWD) across 4 of the largest oncology markets in the world and multimodal data
-
Real-world evidence (RWE) services leveraging Flatiron’s in-house expertise
-
Our clinical trials technology and services enabling prospective evidence generation
Contact us to learn more about Flatiron’s tailored hematology evidence solutions.